Evidence map›Paper›PMID 27308070›Full record

ArticleBalkan medical journal2016

Neuromuscular Dysfunction in Experimental Sepsis and Glutamine.

İlkin Çankayalı, Özden Boyacılar, Kubilay Demirağ, Mehmet Uyar, Ali Reşat Moral

Open access · diamondAbstract read
In one paragraph

Article in Balkan medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

İlkin ÇankayalıDepartment of Anesthesiology and Intensive Care, Ege University School of Medicine, İzmir, Turkey.
Özden BoyacılarDepartment of Anesthesiology and Intensive Care, Ege University School of Medicine, İzmir, Turkey.
Kubilay DemirağDepartment of Anesthesiology and Intensive Care, Ege University School of Medicine, İzmir, Turkey.
Mehmet UyarDepartment of Anesthesiology and Intensive Care, Ege University School of Medicine, İzmir, Turkey.
Ali Reşat MoralDepartment of Anesthesiology and Intensive Care, Ege University School of Medicine, İzmir, Turkey.
Ege University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElectrophysiological studies show that critical illness polyneuromyopathy appears in the early stage of sepsis before the manifestation of clinical findings. The metabolic response observed during sepsis causes glutamine to become a relative essential amino acid.

aimsWe aimed to assess the changes in neuromuscular transmission in the early stage of sepsis after glutamine supplementation. STUDY

designAnimal experimentation.

methodsTwenty male Sprague-Dawley rats were randomized into two groups. Rats in both groups were given normal feeding for one week. In the study group, 1 g/kg/day glutamine was added to normal feeding by feeding tube for one week. Cecal ligation and perforation (CLP) surgery was performed at the end of one week. Before and 24 hours after CLP, compound muscle action potentials were recorded from the gastrocnemius muscle.

resultsLatency measurements before and 24 hours after CLP were 0.68±0.05 ms and 0.80±0.09 ms in the control group and 0.69±0.07 ms and 0.73±0.07 ms in the study group (p<0.05).

conclusionSince enteral glutamine prevented compound muscle action potentials (CMAP) latency prolongation in the early phase of sepsis, it was concluded that enteral glutamine replacement might be promising in the prevention of neuromuscular dysfunction in sepsis; however, further studies are required.

Indexed as

Experimentalglutamineneuromuscularsepsis

Identifiers

PMID27308070
PMCPMC4898985
OpenAlexW2426445378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.